Cargando…
Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation
BACKGROUND: The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate cancer-specific mortality than the traditional three-tiered classification (low, intermediate, and high risk). We investigated radical treatment rates according to CPG in men diagnosed with...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254634/ https://www.ncbi.nlm.nih.gov/pubmed/32460859 http://dx.doi.org/10.1186/s12916-020-01588-9 |
_version_ | 1783539576511397888 |
---|---|
author | Parry, M. G. Cowling, T. E. Sujenthiran, A. Nossiter, J. Berry, B. Cathcart, P. Aggarwal, A. Payne, H. van der Meulen, J. Clarke, N. W. Gnanapragasam, V. J. |
author_facet | Parry, M. G. Cowling, T. E. Sujenthiran, A. Nossiter, J. Berry, B. Cathcart, P. Aggarwal, A. Payne, H. van der Meulen, J. Clarke, N. W. Gnanapragasam, V. J. |
author_sort | Parry, M. G. |
collection | PubMed |
description | BACKGROUND: The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate cancer-specific mortality than the traditional three-tiered classification (low, intermediate, and high risk). We investigated radical treatment rates according to CPG in men diagnosed with non-metastatic prostate cancer in England between 2014 and 2017. METHODS: Patients diagnosed with non-metastatic prostate cancer were identified from the National Prostate Cancer Audit database. Men were risk stratified according to the CPG classification. Risk ratios (RR) were estimated for undergoing radical treatment according to CPG and for receiving radiotherapy for those treated radically. Funnel plots were used to display variation in radical treatment rates across hospitals. RESULTS: A total of 61,999 men were included with 10,963 (17.7%) in CPG1 (lowest risk group), 13,588 (21.9%) in CPG2, 9452 (15.2%) in CPG3, 12,831 (20.7%) in CPG4, and 15,165 (24.5%) in CPG5 (highest risk group). The proportion of men receiving radical treatment increased from 11.3% in CPG1 to 78.8% in CGP4, and 73.3% in CPG5. Men in CPG3 were more likely to receive radical treatment than men in CPG2 (66.3% versus 48.4%; adjusted RR 1.44; 95% CI 1.36–1.53; P < 0.001). Radically treated men in CPG3 were also more likely to receive radiotherapy than men in CPG2 (59.2% versus 43.9%; adjusted RR, 1.18; 95% CI 1.10–1.26). Although radical treatment rates were similar in CPG4 and CPG5 (78.8% versus 73.3%; adjusted RR 1.01; 95% CI 0.98–1.04), more men in CPG5 had radiotherapy than men in CPG4 (79.9% versus 59.1%, adjusted RR 1.26; 95% CI 1.12–1.40). CONCLUSIONS: The CPG classification distributes men in five risk groups that are about equal in size. It reveals differences in treatment practices in men with intermediate-risk disease (CPG2 and CPG3) and in men with high-risk disease (CPG4 and CPGP5) that are not visible when using the traditional three-tiered risk classification. |
format | Online Article Text |
id | pubmed-7254634 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72546342020-06-07 Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation Parry, M. G. Cowling, T. E. Sujenthiran, A. Nossiter, J. Berry, B. Cathcart, P. Aggarwal, A. Payne, H. van der Meulen, J. Clarke, N. W. Gnanapragasam, V. J. BMC Med Research Article BACKGROUND: The five-tiered Cambridge Prognostic Group (CPG) classification is a better predictor of prostate cancer-specific mortality than the traditional three-tiered classification (low, intermediate, and high risk). We investigated radical treatment rates according to CPG in men diagnosed with non-metastatic prostate cancer in England between 2014 and 2017. METHODS: Patients diagnosed with non-metastatic prostate cancer were identified from the National Prostate Cancer Audit database. Men were risk stratified according to the CPG classification. Risk ratios (RR) were estimated for undergoing radical treatment according to CPG and for receiving radiotherapy for those treated radically. Funnel plots were used to display variation in radical treatment rates across hospitals. RESULTS: A total of 61,999 men were included with 10,963 (17.7%) in CPG1 (lowest risk group), 13,588 (21.9%) in CPG2, 9452 (15.2%) in CPG3, 12,831 (20.7%) in CPG4, and 15,165 (24.5%) in CPG5 (highest risk group). The proportion of men receiving radical treatment increased from 11.3% in CPG1 to 78.8% in CGP4, and 73.3% in CPG5. Men in CPG3 were more likely to receive radical treatment than men in CPG2 (66.3% versus 48.4%; adjusted RR 1.44; 95% CI 1.36–1.53; P < 0.001). Radically treated men in CPG3 were also more likely to receive radiotherapy than men in CPG2 (59.2% versus 43.9%; adjusted RR, 1.18; 95% CI 1.10–1.26). Although radical treatment rates were similar in CPG4 and CPG5 (78.8% versus 73.3%; adjusted RR 1.01; 95% CI 0.98–1.04), more men in CPG5 had radiotherapy than men in CPG4 (79.9% versus 59.1%, adjusted RR 1.26; 95% CI 1.12–1.40). CONCLUSIONS: The CPG classification distributes men in five risk groups that are about equal in size. It reveals differences in treatment practices in men with intermediate-risk disease (CPG2 and CPG3) and in men with high-risk disease (CPG4 and CPGP5) that are not visible when using the traditional three-tiered risk classification. BioMed Central 2020-05-28 /pmc/articles/PMC7254634/ /pubmed/32460859 http://dx.doi.org/10.1186/s12916-020-01588-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Parry, M. G. Cowling, T. E. Sujenthiran, A. Nossiter, J. Berry, B. Cathcart, P. Aggarwal, A. Payne, H. van der Meulen, J. Clarke, N. W. Gnanapragasam, V. J. Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation |
title | Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation |
title_full | Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation |
title_fullStr | Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation |
title_full_unstemmed | Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation |
title_short | Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation |
title_sort | risk stratification for prostate cancer management: value of the cambridge prognostic group classification for assessing treatment allocation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254634/ https://www.ncbi.nlm.nih.gov/pubmed/32460859 http://dx.doi.org/10.1186/s12916-020-01588-9 |
work_keys_str_mv | AT parrymg riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation AT cowlingte riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation AT sujenthirana riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation AT nossiterj riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation AT berryb riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation AT cathcartp riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation AT aggarwala riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation AT payneh riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation AT vandermeulenj riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation AT clarkenw riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation AT gnanapragasamvj riskstratificationforprostatecancermanagementvalueofthecambridgeprognosticgroupclassificationforassessingtreatmentallocation |